TARGET Based m 6 A Methylation-Related Genes Predict Prognosis Relapsed B-cell Acute Lymphoblastic Leukemia

Abstract

Purpose The current study aim to investigate the significance of N6-methyladenosine (m⁶A) methylationrelated genes in the clinical prognosis of childhood relapsed B-cell acute lymphoblastic leukemia patient. Methods Transcriptome data and corresponding clinical data on m⁶A methylation-related genes (including 20 genes) were obtained from the Therapeutically Applicable Research To Generate Effective Treatments (TARGET) database. Results The bone marrow (BM) samples of 134 newly diagnosed (naive) and 116 relapsed B-ALL from TARGET were enrolled in the current study. Three genes (FTO, HNRNPC, RBM15B) showed significant up-regulation in relapsed B-ALL compared with that in naive B-ALL.The three genes had a significantly worse survival (P < 0.05). The LASSO Cox regression model was used to select the most predictive genes as prognostic indicators, and YTHDC1 and FTO were identified as prognostic factors for relapsed ALL. Finally, the results of multivariate regression analysis showed that the risk score of m⁶A methylation-related genes was an independent prognostic factor in relapsed B-ALL (P < 0.05). Conclusion We found that the expression levels of m⁶A methylation-related genes were different in naive and relapsed patients with B-ALL and correlated with survival and prognosis.This implies that m⁶A methylation-related genes may be promising prognostic indicators or therapeutic targets for relapsed B-ALL.